Summary

Hypertrophic cardiomyopathy (HCM) has a prevalence of 1 in every 500 individuals, making it the most frequently inherited cardiomyopathy, and it results in the fibrosis and hypertrophy of the left ventricle. This article discusses data from the Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy [INHERIT; NCT01447654] trial, which investigated the use of losartan for HCM.